Vimarsana
Biggest News Aggregation in the World

Page 2 - Joseph Stringer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Joseph Stringer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Joseph Stringer Today - Breaking & Trending Today

Robert "Bob" Stringer - Vimarsana News

Robert "Bob" Stringer

BRASELTON - Robert "Bob" Stringer, 84, passed away on Thursday, August 17, 2023, at his home in Braselton.

Robert "Bob" Stringer - Vimarsana News

Robert "Bob" Stringer

BRASELTON - Robert "Bob" Stringer, 84, passed away on Thursday, August 17, 2023, at his home in Braselton.

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript - Vimarsana News

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript August 7, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.00058 EPS, expectations were $0.56. Operator: Thank you for standing by, and welcome to Cara Therapeutics’ Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. […]

Source: yahoo.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2023 Earnings Call Transcript - Vimarsana News

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to Apellis Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline - Vertex Pharmaceuticals (NASDAQ:VRTX) - Vimarsana News

Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline - Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 bill